ARCUTIS BIOTHERAPEUTICS INC's ticker is ARQT and the CUSIP is 03969K108. A total of 145 filers reported holding ARCUTIS BIOTHERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 0.34 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,226,531 | -53.3% | 419,309 | -16.1% | 0.01% | -51.9% |
| Q2 2023 | $4,764,257 | +42.1% | 499,922 | +64.1% | 0.03% | +17.4% |
| Q1 2023 | $3,351,766 | -25.3% | 304,706 | +0.5% | 0.02% | -39.5% |
| Q4 2022 | $4,486,309 | +34.9% | 303,129 | +74.2% | 0.04% | +8.6% |
| Q3 2022 | $3,325,000 | +268.2% | 173,983 | +310.6% | 0.04% | +337.5% |
| Q2 2022 | $903,000 | -18.1% | 42,377 | -26.0% | 0.01% | +14.3% |
| Q1 2022 | $1,103,000 | -6.4% | 57,259 | +0.7% | 0.01% | +16.7% |
| Q4 2021 | $1,179,000 | +63.3% | 56,850 | +88.1% | 0.01% | +20.0% |
| Q3 2021 | $722,000 | -29.9% | 30,223 | -20.0% | 0.01% | -16.7% |
| Q2 2021 | $1,030,000 | -14.6% | 37,761 | -9.4% | 0.01% | -25.0% |
| Q1 2021 | $1,206,000 | +466.2% | 41,693 | +451.3% | 0.01% | +300.0% |
| Q4 2020 | $213,000 | – | 7,563 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 8,434,232 | $162,443,000 | 13.84% |
| Bain Capital Life Sciences Investors, LLC | 3,979,292 | $76,641,000 | 7.44% |
| Pivotal bioVenture Partners Investment Advisor LLC | 569,041 | $10,960,000 | 5.19% |
| Logos Global Management LP | 1,500,000 | $28,890,000 | 3.75% |
| Omega Fund Management, LLC | 623,836 | $12,015,000 | 2.46% |
| Orbimed Advisors | 6,073,850 | $116,982,000 | 1.90% |
| MPM BioImpact LLC | 258,500 | $4,979,000 | 1.34% |
| 1492 Capital Management LLC | 75,192 | $1,448,000 | 0.77% |
| SECTORAL ASSET MANAGEMENT INC | 219,136 | $4,221,000 | 0.75% |
| EcoR1 Capital, LLC | 895,503 | $17,247,000 | 0.54% |